Feng Shuo, Fowlkes Ashley L, Steffens Andrea, Finelli Lyn, Cowling Benjamin J
From the aWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; and bInfluenza Division, Centers for Disease Control and Prevention, Atlanta, GA.
Epidemiology. 2017 Jul;28(4):514-524. doi: 10.1097/EDE.0000000000000670.
The observational test-negative study design is used to estimate vaccine effectiveness against influenza virus infection. An important assumption of the test-negative design is that vaccination does not affect the risk of infection with another virus. If such virus interference occurred, detection of other respiratory viruses would be more common among influenza vaccine recipients and vaccine effectiveness estimates could differ. We evaluated the potential for virus interference using data from the Influenza Incidence Surveillance Project.
From 2010 to 2013, outpatients presenting to clinics in 13 US jurisdictions with acute respiratory infections were tested for influenza and other respiratory viruses. We investigated whether virus interference might affect vaccine effectiveness estimates by first evaluating the sensitivity of estimates using alternative control groups that include or exclude patients with other respiratory virus detections by age group and early/middle/late stage of influenza seasons. Second, we evaluated the association between influenza vaccination receipt and other respiratory virus detection among influenza test-negative patients.
Influenza was detected in 3,743/10,650 patients (35%), and overall vaccine effectiveness was 47% (95% CI: 42%, 52%). Estimates using each control group were consistent overall or when stratified by age groups, and there were no differences among early, middle, or late phase during influenza season. We found no associations between detection of other respiratory viruses and receipt of influenza vaccination.
In this 3-year test-negative design study in an outpatient setting in the United States, we found no evidence of virus interference or impact on influenza vaccine effectiveness estimation.
观察性检测阴性研究设计用于评估流感病毒感染的疫苗效力。检测阴性设计的一个重要假设是接种疫苗不会影响感染其他病毒的风险。如果发生这种病毒干扰,在流感疫苗接种者中检测到其他呼吸道病毒的情况会更常见,疫苗效力估计值可能会有所不同。我们利用流感发病率监测项目的数据评估了病毒干扰的可能性。
2010年至2013年,对美国13个司法管辖区诊所中出现急性呼吸道感染的门诊患者进行流感和其他呼吸道病毒检测。我们首先通过使用替代对照组评估估计值的敏感性,这些对照组按年龄组以及流感季节的早期/中期/晚期纳入或排除检测到其他呼吸道病毒的患者,以此调查病毒干扰是否可能影响疫苗效力估计值。其次,我们评估了流感检测阴性患者中流感疫苗接种与其他呼吸道病毒检测之间的关联。
在10650名患者中有3743名(35%)检测到流感,总体疫苗效力为47%(95%置信区间:42%,52%)。使用每个对照组的估计值总体上是一致的,或按年龄组分层时是一致的,且在流感季节的早期、中期或晚期之间没有差异。我们发现其他呼吸道病毒检测与流感疫苗接种之间没有关联。
在这项针对美国门诊环境的为期3年的检测阴性设计研究中,我们没有发现病毒干扰或对流感疫苗效力估计产生影响的证据。